What does testosterone do in women?
In women, testosterone acts through androgen receptors distributed across multiple tissues, including the brain, bone, muscle, adipose tissue, and skin. The physiological roles include:
- Sexual desire: Testosterone is the primary driver of libido in both sexes. The hypothalamic pathways that generate sexual motivation are androgen-dependent. Low testosterone is one of the most mechanistically direct causes of hypoactive sexual desire.
- Muscle mass and strength: Testosterone supports protein synthesis and muscle fiber maintenance. Women with confirmed testosterone deficiency commonly report reduced muscular endurance and slower recovery from exercise.
- Bone density: Testosterone contributes to bone mineral density maintenance alongside estrogen. Its decline may compound the risk of osteoporosis in the perimenopausal transition.
- Energy and mood: Androgen receptors in the brain influence dopaminergic signaling pathways involved in motivation, energy level, and mood. Low-testosterone women commonly describe a flattened affect and difficulty summoning motivation that is distinct from the mood changes attributable to estrogen deficiency.
- Cognitive function: Some evidence points to a role for testosterone in verbal memory and processing speed in women, though the evidence base here is less definitive than in the domains above.
What are normal testosterone levels in women, and how do they change over time?
Testosterone exists in different forms in the blood: total testosterone, free testosterone (unbound and biologically active), and sex hormone-binding globulin (SHBG)-bound testosterone (largely inactive). Lab interpretation in women requires measuring all three, because SHBG levels (which change with estrogen and other hormones) significantly affect how much free testosterone is available.
Testosterone in premenopausal women peaks in the mid-20s and declines by approximately 50% by the time a woman reaches her mid-40s. Surgical menopause (bilateral oophorectomy) causes a more abrupt decline, as the ovaries are the primary testosterone-producing organ. Natural menopause produces a more gradual decline, with some continued production from the adrenal glands and peripheral conversion.
There is no universally agreed-upon lower threshold for female testosterone deficiency; this is an active area of endocrinological debate. What clinicians use in practice is the combination of labs below the lower quartile of the normal female range and symptoms consistent with androgen insufficiency. Both elements are needed for the clinical diagnosis.
What does the evidence show about testosterone therapy in women?
The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published jointly by major endocrinology and gynecology societies including the Endocrine Society, the International Menopause Society, and the British Menopause Society, represents the strongest synthesis of the evidence to date.
Key findings from the position statement and the systematic reviews it incorporated:
- Hypoactive sexual desire disorder (HSDD): Testosterone therapy has the strongest evidence base for addressing low libido in postmenopausal women. Multiple randomized controlled trials support its efficacy for this indication. The Global Consensus statement endorses testosterone for this use when other causes of low desire have been evaluated.
- Mood and well-being: Some trials have found improvements in mood, energy, and general well-being, though effects are less consistent than the libido findings.
- Musculoskeletal: Evidence for muscle strength and bone density effects in women exists but is less robust than in male TRT studies, partly because the female-specific evidence base is smaller.
- Long-term safety: The statement notes that the evidence on long-term safety beyond 24 months is limited, and that cardiovascular and breast cancer risks at physiological doses appear acceptable based on current data but require ongoing monitoring.
The consensus statement is explicit: testosterone should be prescribed at doses that achieve physiological female concentrations, not supraphysiological levels. The safety profile changes when doses push levels above the female normal range.
The goal of testosterone therapy in women is to restore the normal female range — never to reach male levels.
Which testosterone formulations are used in women?
There is no FDA-approved testosterone product specifically for women in the United States. Women who receive testosterone therapy are prescribed off-label male formulations at fractional doses, or they receive compounded formulations tailored to female dosing ranges. The most commonly used approaches include:
- Compounded creams or gels: Applied topically, typically to the inner thigh or forearm. Low-dose compounded formulations allow for precise dose titration appropriate for female physiology. This is among the most practical options for female TRT.
- Off-label male gel at fractional doses: Some clinicians use male formulations at 5-10% of the male dose. This requires careful attention to dose precision.
- Pellet implants: Subcutaneous pellets that release testosterone over months. Used by some clinicians but criticized in the evidence base for making dose adjustment difficult if side effects emerge.
- Injections: Less commonly used in women given the difficulty of precise low-dose administration with most commercially available injectable formulations.
How do testosterone doses differ between women and men?
The dosing difference between female and male testosterone therapy is substantial. The table below summarizes the key distinctions based on the clinical principles described in the 2019 Global Consensus Position Statement and the evidence referenced on this page.
| Parameter | Women | Men |
|---|---|---|
| Relative dose | 5–10% of male dose | Full replacement dose |
| Target range | Normal female physiological range | Normal male physiological range |
| Common formulations | Compounded creams/gels; off-label male gel at fraction; pellets (less preferred) | Gels, injections, pellets, patches |
| FDA-approved product | None for women specifically | Multiple approved products |
| Primary evidence base | HSDD in postmenopausal women; mood and well-being | Hypogonadism; muscle mass; energy |
| Monitoring frequency | 4–6 weeks post-initiation; every 6–12 months stable | Similar cadence per clinical protocol |
What monitoring and safety considerations apply?
Clinician-supervised testosterone therapy in women requires regular laboratory monitoring, typically at 4-6 weeks after initiating or adjusting a dose and then every 6-12 months once stable. Labs include:
- Total and free testosterone to confirm levels remain within physiological female range
- SHBG, as changes in SHBG affect free testosterone availability
- Hematocrit if high doses or injectable formulations are used
- Lipid panel at baseline and periodically
The main adverse effects to monitor for are signs of virilization: acne, increased body or facial hair, voice changes, and clitoral enlargement. These generally indicate that doses are too high or that absorption is higher than expected. Catching them early through regular follow-up allows dose reduction before effects become permanent.
Women with a history of hormone-sensitive cancers, including certain breast cancers, are generally not candidates for testosterone therapy without specialized oncology input. A thorough review of health history is part of the clinical evaluation before prescribing.
How do you get evaluated for female TRT?
A starting point is distinguishing whether the symptoms driving the question (fatigue, low libido, mood changes, muscle loss) are more likely attributable to testosterone deficiency, estrogen deficiency, thyroid dysfunction, other hormonal imbalances, or non-hormonal causes. Each has different treatments. Labs are the starting point for that distinction.
- Complete the intake assessment. Answer questions about your symptoms and health history, including any hormone-sensitive conditions, as directed by your clinician.
- Clinician reviews your case. A licensed clinician evaluates your responses, flags contraindications, and determines whether lab testing is appropriate for your situation.
- Lab testing is ordered. Total testosterone, free testosterone, SHBG, and relevant safety markers are drawn to establish your baseline before any prescribing decision is made.
- Clinician prescribes if appropriate. If labs and symptom picture support a diagnosis of androgen insufficiency and no contraindications are present, the clinician prescribes low-dose testosterone as directed — compounded by licensed 503A pharmacies in the USA.
- Ongoing monitoring. Follow-up labs at 4–6 weeks after any dose change, then every 6–12 months, confirm levels stay within the physiological female range.
PepScribe offers clinician-supervised hormonal evaluations that include review for androgen insufficiency in women. Testosterone for women is a prescription medication; a clinician determines whether it is appropriate for your situation. Compounded formulations, where prescribed, are prepared by licensed 503A pharmacies in the USA — no hidden overseas supply chain.